[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio30376b8f":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":77},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio30376b8f","美股TRAX今天为什么大涨？","\u002Fdoc\u002Fdcio30376b8f","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">First Tracks Biotherapeutics, Inc.\u003Cspan style=\"font-family: DengXian;\">（纳斯达克代码：\u003C\u002Fspan>TRAX\u003Cspan style=\"font-family: DengXian;\">）在今天（\u003C\u002Fspan>2026\u003Cspan style=\"font-family: DengXian;\">年\u003C\u002Fspan>7\u003Cspan style=\"font-family: DengXian;\">月\u003C\u002Fspan>9\u003Cspan style=\"font-family: DengXian;\">日）盘中暴涨超过\u003C\u002Fspan> 54%\u003Cspan style=\"font-family: DengXian;\">，股价最高触及\u003C\u002Fspan> $32.30\u003Cspan style=\"font-family: DengXian;\">。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">这次爆发的核心原因并不是公司自身发布了直观的公告，而是医药界的一场“同机制临床正面映射效应”（\u003C\u002Fspan>Positive Read-through Effect\u003Cspan style=\"font-family: DengXian;\">），加之华尔街分析师在今早的强力唱多，瞬间点燃了资金的抢跑热情。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">美股投资网拆解具体原因，可以为以下三个核心维度：\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">1. \u003Cspan style=\"font-family: DengXian;\">行业巨头梯瓦（\u003C\u002Fspan>Teva\u003Cspan style=\"font-family: DengXian;\">）靶点大获成功，形成“降维验证”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">前天（\u003C\u002Fspan>7\u003Cspan style=\"font-family: DengXian;\">月\u003C\u002Fspan>7\u003Cspan style=\"font-family: DengXian;\">日），制药巨头梯瓦制药公布了其自主研发的抗\u003C\u002Fspan> IL-15 \u003Cspan style=\"font-family: DengXian;\">单克隆抗体\u003C\u002Fspan> TEV-408 \u003Cspan style=\"font-family: DengXian;\">在治疗白癜风（\u003C\u002Fspan>Vitiligo\u003Cspan style=\"font-family: DengXian;\">）的\u003C\u002Fspan> Phase 1b \u003Cspan style=\"font-family: DengXian;\">临床试验中取得了极具颠覆性的正面数据，不仅清斑效果显著、耐受性极好，并宣布将在今年第四季度直接推进至\u003C\u002Fspan> Phase 2b \u003Cspan style=\"font-family: DengXian;\">阶段。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">为什么这跟\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">直接挂钩？\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">TRAX \u003Cspan style=\"font-family: DengXian;\">旗下最核心、被寄予厚望的资产\u003C\u002Fspan> ANB033 \u003Cspan style=\"font-family: DengXian;\">是一种\u003C\u002Fspan> CD122 \u003Cspan style=\"font-family: DengXian;\">拮抗剂。而\u003C\u002Fspan> CD122 \u003Cspan style=\"font-family: DengXian;\">正是\u003C\u002Fspan> IL-15 \u003Cspan style=\"font-family: DengXian;\">和\u003C\u002Fspan> IL-2 \u003Cspan style=\"font-family: DengXian;\">受体共享的\u003C\u002Fspan> beta \u003Cspan style=\"font-family: DengXian;\">亚基。换句话说，梯瓦的抗\u003C\u002Fspan> IL-15 \u003Cspan style=\"font-family: DengXian;\">药物在人体临床上的巨大成功，直接帮\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">彻底验证了\u003C\u002Fspan> IL-15 \u003Cspan style=\"font-family: DengXian;\">这条免疫通路在自身免疫疾病中的强效可行性与安全性。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">2. \u003Cspan style=\"font-family: DengXian;\">核心管线确定性暴增，引爆年内关键数据预期\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">梯瓦的\u003C\u002Fspan> TEV-408 \u003Cspan style=\"font-family: DengXian;\">不仅在皮肤自免领域有效，目前也正在开展治疗乳糜泻（\u003C\u002Fspan>Celiac Disease\u003Cspan style=\"font-family: DengXian;\">）的\u003C\u002Fspan> Phase 2a \u003Cspan style=\"font-family: DengXian;\">临床试验。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">而巧合的是，\u003C\u002Fspan>TRAX \u003Cspan style=\"font-family: DengXian;\">的\u003C\u002Fspan> ANB033 \u003Cspan style=\"font-family: DengXian;\">目前正在推进的核心临床，同样是针对乳糜泻（\u003C\u002Fspan>Celiac Disease\u003Cspan style=\"font-family: DengXian;\">）和嗜酸性粒细胞性食管炎（\u003C\u002Fspan>EoE\u003Cspan style=\"font-family: DengXian;\">）的\u003C\u002Fspan> Phase 1b \u003Cspan style=\"font-family: DengXian;\">试验。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">催化剂时间明确：\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">官方预计将在\u003C\u002Fspan> 2026 \u003Cspan style=\"font-family: DengXian;\">年第四季度（也就是几个月后）公布\u003C\u002Fspan> ANB033 \u003Cspan style=\"font-family: DengXian;\">治疗乳糜泻的顶线数据（\u003C\u002Fspan>Top-line data\u003Cspan style=\"font-family: DengXian;\">）。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">资金疯狂抢跑：\u003C\u002Fspan>\u003Cspan style=\"font-family: DengXian;\">梯瓦的临床成功向市场证明了该靶点在乳糜泻上拥有至少\u003C\u002Fspan> 15 \u003Cspan style=\"font-family: DengXian;\">亿美元年销售额的潜在空间，相当于提前帮\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">排除了一大半的临床“踩雷”风险。这让投资者对\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">年底的数据信心大增，导致盘面资金疯狂扫货。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">3. \u003Cspan style=\"font-family: DengXian;\">华尔街知名投行今天开盘前“推波助澜”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">今天（\u003C\u002Fspan>7\u003Cspan style=\"font-family: DengXian;\">月\u003C\u002Fspan>9\u003Cspan style=\"font-family: DengXian;\">日）早间，知名投行\u003C\u002Fspan> H.C. Wainwright \u003Cspan style=\"font-family: DengXian;\">的明星分析师\u003C\u002Fspan> Emily Bodnar \u003Cspan style=\"font-family: DengXian;\">发布研究报告，明确指出梯瓦的临床大捷对\u003C\u002Fspan> First Tracks\u003Cspan style=\"font-family: DengXian;\">（\u003C\u002Fspan>TRAX\u003Cspan style=\"font-family: DengXian;\">）是直接的重大利好。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">评级与目标价：\u003C\u002Fspan> H.C. Wainwright \u003Cspan style=\"font-family: DengXian;\">重申对\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">的“买入”（\u003C\u002Fspan>Buy\u003Cspan style=\"font-family: DengXian;\">）评级。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">机构共识形成合力：\u003C\u002Fspan>\u003Cspan style=\"font-family: DengXian;\">实际上，目前华尔街对\u003C\u002Fspan> TRAX \u003Cspan style=\"font-family: DengXian;\">的共识评级是极罕见的“强推买入”（\u003C\u002Fspan>Strong Buy\u003Cspan style=\"font-family: DengXian;\">），包括摩根大通（\u003C\u002Fspan>JPMorgan\u003Cspan style=\"font-family: DengXian;\">）、巴克莱（\u003C\u002Fspan>Barclays\u003Cspan style=\"font-family: DengXian;\">）、\u003C\u002Fspan>Piper Sandler \u003Cspan style=\"font-family: DengXian;\">在内的\u003C\u002Fspan> 8 \u003Cspan style=\"font-family: DengXian;\">家主力机构此前给出的平均目标价就在\u003C\u002Fspan> $38 \u003Cspan style=\"font-family: DengXian;\">左右。今天梯瓦的外部催化剂成了导火索，将这些潜在的乐观情绪瞬间变现为了盘面的疯狂买单。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: 'Segoe UI Emoji', sans-serif;\">","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FT\u002FTRAX\u002FTRAX.jpg","2026-07-09T21:15:15","2026.07.09","2026\u002F07\u002F09",30384,[22],"TRAX","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":68,"summaryHtml":73,"aboutTitle":74,"aboutHtml":75,"copyrightHtml":76},[44,47,50,53,56,59,62,65],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":60,"url":61},"美股课程","\u002Fcol\u002Fvideos",{"label":63,"url":64},"免责声明","\u002Fdisclaimer",{"label":66,"url":67},"联系我们","\u002FContactUs",[69,70,71,72],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" target=\"_blank\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":78,"search":79,"searchPlaceholder":79,"hotContent":80,"draft":81,"noData":82,"searchNoData":83,"edit":84,"editVideo":85,"courseContent":86,"more":87,"buyNow":88,"subscribeNow":89,"encoding":90,"paidContent":91},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]